Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders. 2007;8:27.
Almansa C, Rey E, Sánchez RG, Sánchez AA, Díaz-Rubio M. Prevalence of functional gastrointestinal disorders in patients with fibromyalgia and the role of psychologic distress. Clin Gastroenterol Hepatol. 2009;7:438–45.
Pamuk ON, Umit H, Harmandar O. Increased frequency of gastrointestinal symptoms in patients with fibromyalgia and associated factors: a comparative study. J Rheumatol. 2009;36:1720–4.
Rome III. Rome Foundation website: http://www.romecriteria.org/ (Accessed March 2008.)
Halder SL, Locke GR, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology. 2007;133:799–807.
Hungin AS, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643–50.
Gómez Alvarez DF, Morales Vargas JG, Rojas Medina LM, et al. Prevalence of irritable bowel syndrome and associated factors according to the Rome III diagnostic criteria in a general population in Colombia. Gatroenterol Hepatol. 2009;32:395–400.
Faresjö A, Grodzinsky E, Johansson S, et al. A population-based case-control study of work and psychosocial problems in patients with irritable bowel syndrome – women are more seriously affected than men. Am J Gastroenterol. 2007;102:371–9.
Riedl A, Schmidtmann M, Stengel A, et al. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res. 2008;64:573–82.
Moshiree B, Price DD, Robinson ME, Gaible R, Verne GN. Thermal and visceral hypersensitivity in irritable bowel syndrome patients with and without fibromyalgia. Clin J Pain. 2007;23:323–30.
Olden KW. The challenge of diagnosing irritable bowel syndrome. Rev Gastroenterol Dis. 2003;3:S3–11.
Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut. 2004;53:666–72.
Videlock EJ, Chang L. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin N Am. 2007;36:665–85.
Holten KB. Irritable bowel syndrome: minimize testing, let symptoms guide treatment. J Fam Pract. 2003;52:942–9.
Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med. 2003;163:265–74.
Reitblat T, Zamir D, Polishchuck I, et al. Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study. Clin Rheumatol. 2009;29:1079–82.
Owen RT. Lubiprostone – a novel treatment for irritable bowel syndrome with constipation. Drugs Today (Barc). 2008;44:645–52.
Lacy BE, Chey WD. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother. 2009;10:143–52.
Drossman DA, Chey WD, Johanson JF, et al. Clinilca trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Alimen Pharmacol Ther. 2009;29:329–41.
Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:981–9.
Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56:1218–25.
Gale JD. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Adv Ther. 2009;26:519–30.
George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome – a multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther. 2008;27:830–7.
Andresen V, Camilleri M, Busciqlio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133:761–8.
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastsroenterol. 2009;15:1548–53.
Brennan BP, Fogarty KV, Roberts JL, et al. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol. 2009;24:423–8.
Shen YA, Nahas R. Complementary and alternative medicine for treatment of irritable bowel syndrome. Can Fam Physician. 2009;55:143–8.
Lembo AJ, Conboy L, Kelley JM. A treatment trial of acupuncture in IBS patients. Am J Gastroenterol. 2009;104:1489–97.
Mikocka-Walus A, Turnbull D, Moulding N, et al. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. J Gastroenterol Hepatol. 2008;23:1137–43.
Hertig VL, Cain KC, Jarrett ME, Burr RL, Heitkemper MM. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res. 2007;56:399–406.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Marcus, D.A., Deodhar, A. (2011). Irritable Bowel Syndrome. In: Fibromyalgia. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1609-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1609-9_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1608-2
Online ISBN: 978-1-4419-1609-9
eBook Packages: MedicineMedicine (R0)